(Q26750720)

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Toxicity of primaquine in Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Toxicity of primaquine in Negroes

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Mechanisms of cytochrome P450 substrate oxidation: MiniReview

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

MSE with mass defect filtering for in vitro and in vivo metabolite identification

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Activated oxygen generation by a primaquine metabolite: inhibition by antioxidants derived from Chinese herbal remedies

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Primaquine revisited six decades after its discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Evidence of the formation of direct covalent adducts of primaquine, 2-tert-butylprimaquine (NP-96) and monohydroxy metabolite of NP-96 with glutathione and N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Reticulocytes from cryopreserved erythroblasts support Plasmodium vivax infection in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Do hypnozoites cause relapse in malaria?

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Human iPSC-derived hepatocyte-like cells support Plasmodium liver-stage infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Glucose-6-phosphate dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Alkylaminoalkyl Derivatives of 8-Aminoquinoline1

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Synthesis of certain hydroxy analogues of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Rapid aromatic hydrogen exchange in the antimalarial primaquine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Primaquine for prophylaxis of malaria: has the CYP sailed?

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Enantioselective pharmacokinetics of primaquine in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetic interactions between primaquine and chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Relapses in primate malaria: discovery of two populations of exoerythrocytic stages. Preliminary note

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Molecular mechanisms of genetic polymorphisms of drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

PROCEDURES USED AT STATEVILLE PENITENTIARY FOR THE TESTING OF POTENTIAL ANTIMALARIAL AGENTS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Primaquine: the risks and the benefits

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Enantioselective metabolism of primaquine by human CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Peroxidation of the antimalarial drug primaquine: characterization of a benzidine-like metabolite with methaemoglobin-forming activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021

Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.03.011

7 January 2021